Phase II study of ERC1671 plus bevacizumab versus bevacizumab plus placebo in recurrent glioblastoma: interim results and correlations with CD4+T-lymphocyte counts
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.